雖然這篇Nct01730534鄉民發文沒有被收入到精華區：在Nct01730534這個話題中，我們另外找到其它相關的精選爆讚文章
[爆卦]Nct01730534是什麼？優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
#1Multicenter Trial to Evaluate the Effect of Dapagliflozin on the ...
ClinicalTrials.gov Identifier: NCT01730534. Recruitment Status : Completed. First Posted : November 21, 2012. Results First Posted : December 26, 2019.
-
#2Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
(Funded by AstraZeneca; DECLARE–TIMI 58 ClinicalTrials.gov number, NCT01730534. opens in new tab.) Introduction.
-
#3NCT01730534: A reported trial by AstraZeneca - FDAAA Trials Tracker
Full entry on ClinicalTrials.gov, NCT01730534. Title, Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, ...
-
#4The design and rationale for the Dapagliflozin Effect ... - PubMed
由 SD Wiviott 著作 · 2018 · 被引用 127 次 — Research design and methods: DECLARE-TIMI 58 (NCT01730534) is a phase 3b randomized, double-blind, placebo-controlled trial designed to evaluate the CV ...
-
#5ClinicalTrials.gov - ICTRP Search Portal
Main ID: NCT01730534. Date of registration: 15/11/2012. Prospective Registration: Yes. Primary sponsor: AstraZeneca. Public title: Multicenter Trial to ...
-
#6Multicenter Trial to Evaluate the Effect of ... - Cochrane Library
NCT01730534. https://clinicaltrials.gov/show/NCT01730534, 2012 | added to CENTRAL: 31 May 2018 | 2018 Issue 5. Sourced from:.
-
#7The Dapagliflozin Effects on Cardiovascular Events ...
DapaCare involves nearly 30,000 patients across RCTs and is supported by a large real-world cohort. ▫ DapaCare includes a spectrum of patients, ...
-
#8Dapagliflozin and cardiovascular outcomes: anything else ... - X-MOL
Areas covered: In this paper, the authors critically discuss the background, trial design, results and implications of a recent CVOT [NCT01730534; ...
-
#9NCT01730534 - SBEM SC
CV, cardiovascular; DKA, diabetic ketoacidosis; ECVD, established atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; ...
-
#10Medline ® Abstract for Reference 55 of 'Treatment of diabetic ...
DECLARE-TIMI 58 is registered with ClinicalTrials.gov, number NCT01730534. FINDINGS The trial took place between April 25, 2013, and Sept 18, 2018; ...
-
#11Cardiovascular outcomes trials with various ...
Ongoin g studies ¥ Dapagliflozin (DECLARE-TIMI 58); NCT01730534 Ertugliflozin (VERTIS CV); NCT01986881 Dapagliflozin (Dapa-HF); NCT03036124 Empagliflozin ...
-
#13Organization | TIMI Study Group, Boston, MA - Clinical Drug ...
NCT01730534. 2013. Trial Started. NCT01730534. 2020. 2020. Trial Started. NCT04409834. 2020. Trial Started. NCT04409834. 2020. Trial Started.
-
#14Dapagliflozin Completed Phase 3 Trials for High Risk for ...
NCT01730534, Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events. Dapagliflozin (DB06292) ...
-
#15Essais cliniques sur Diabetes Mellitus, Non-Insulin-Dependent ...
Cette étude est fondée pour déterminer l'effet de la dapagliflozine sur les troubles cardiovasculaires. résultats lorsqu'il est ajouté au traitement de fond ...
-
#16Multicenter Trial to Evaluate the Effect of Dapagliflozin ... - Meta
2022 Meta ULC. All rights reserved. NCT: NCT01730534Nov 21, 2012Clinical Trial. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence ...
-
#17Urinary glucose excretion via SGLT2 inhibition
Daily. □ Liraglutide: ▫ Victoza. ▫ Saxenda (obesity dosing). ▫ Xultophy (Liraglutide & Insulin-Degludec). □ Lixisenatid. ▫ Lyxumia.
-
#18Kidney outcomes using a sustained ≥40% decline in eGFR
The trials assessed were VERTIS CV (NCT01986881), CANVAS Program (NCT01032629 and NCT01989754), DECLARE-TIMI 58 (NCT01730534), and EMPA-REG OUTCOME ...
-
#19Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 ...
Unique identifier: NCT01730534. Clinical Perspective. What Is New? DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular ...
-
#20Table 1. Comparative description of the major SGLT2i studies ...
Clinical trial registration, NCT01131676, NCT01032629 and NCT01989754, NCT01730534, NCT01986881 ; Intervention, Empagliflozin versus placebo, Canagliflozin ...
-
#21INVOKANA - The CANVAS Program – Comparison to DECLARE ...
NCT01730534. N, N=10,142, N=17,160. CV Disease history (65%): n=6656, No CV disease history (35%): n=3486, Established CV disease:(40.6%)n=6974
-
#22The efficacy and safety of dapagliflozin in women and men ...
由 ML O’Donoghue 著作 · 2021 · 被引用 3 次 — Trial registration: clinicaltrials.gov NCT01730534. Graphical abstract: [Figure not available: see fulltext.] Original language, English (US).
-
#23The design and rationale for the Dapagliflozin ... - Researcher
Research design and methods DECLARE–TIMI 58 ( NCT01730534 ) is a phase 3b randomized, double-blind, placebo-controlled trial designed to evaluate the CV ...
-
#24an analysis from the DECLARE-TIMI 58 randomised trial
... of these composite outcomes, and changes in eGFR at different timepoints. DECLARE-TIMI 58 is registered with ClinicalTrials.gov, number NCT01730534.
-
#25The design and rationale for the Dapagliflozin ... - EM consulte
DECLARE–TIMI 58 (NCT01730534) is a phase 3b randomized, double-blind, placebo-controlled trial designed to evaluate the CV safety and efficacy of ...
-
#26Farxiga strengthens kidney case for type 2 diabetes drugs
Renal outcomes data from Declare-Timi, NCT01730534. Endpoint, Farxiga, Placebo, Stats. Renal-specific composite*, 1.5%, 2.8%, HR 0.53, ...
-
#27Dapagliflozin and cardiovascular outcomes in type 2 diabetes
GOV IDENTIFIER NCT01730534. PMID 30415602. URL ID http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85060042753&origin=inward; ...
-
#28View of Should All Patients with Type 2 Diabetes Mellitus and ...
16 Identifier NCT01730534: Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58).
-
#29研究的品質有多好(內在效度)？
dapagliflozin (DECLARE–TIMI58, NCT01730534). Victoza®. (Liraglutide). Jardiance®. (Empagliflozin ). Forxiga®. (Dapagliflozin).
-
#30Dapagliflozin and cardiovascular outcomes ... - Scholars@UAB
... finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARETIMI 58 ClinicalTrials.gov number, NCT01730534, ...
-
#31Table 1 Basic characteristics of CVOTs started after 2008 FDA ...
Study status Drug Drug class Primary Outcome N SAVOR‑TIMI53 Completed Saxagliptin DPP‑4 inhibitor CV death, MI, or stroke 18,206 EXAMINE Completed Alogliptin DPP‑4 inhibitor CV death, MI, or stroke 5380 TECOS Completed Sitagliptin DPP‑4 inhibitor CV death, MI, UA, or stroke 14,724
-
#32Dapagliflozin Effect on Cardiovascular Events A Multicenter ...
NCT ID: NCT01730534. Secondary ID: Study Acronym: ... ClinicalTrials.gov Link: https://clinicaltrials.gov/show/NCT01730534. Overall Status: Completed ...
-
#33Effect of Dapagliflozin on Cardiovascular Outcomes According ...
Trial Registration ClinicalTrials.gov Identifier: NCT01730534. Full Text. Comment. Limit 200 characters. Limit 25 characters.
-
#34心血管系イベントに及ぼすダパグリフロジンの作用。2型 ...
関連ID, NCT01730534: ClinicalTrials.gov. 対象疾患. 試験実施者, アストラゼネカ株式会社. 試験の種類, 介入試験. 試験の概要, 心血管系疾患、又は心血管危険因子を ...
-
#35Farxiga achieved a positive result in the Phase ... - AstraZeneca
... Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI 58). Sept. 2018. https://clinicaltrials.gov/ct2/show/NCT01730534.
-
#36Dapagliflozin reduced cardiorenal outcomes but not MACE in ...
Randomized placebo-controlled trial (Dapagliflozin Effect on Cardiovascular Events [DECLARE]–TIMI 58 trial). ClinicalTrials.gov NCT01730534.
-
#37更新履歴 / update history information - 臨床試験情報詳細画面 ...
他の登録機関でのID番号secondary ID no. NCT01730534. IPD共有に関する計画plan to share IPD, 無 / no. IPD共有に関する計画の ...
-
#38Study Design | T2D and Multiple CV Risk Factors - FARXIGA ...
ClinicalTrials.gov identifier: NCT01730534. Updated December 26, 2019. Accessed November 11, 2020. https://www.clinicaltrials.gov/ct2/show/results/ ...
-
#39Clube de Revista Especial: os destaques em prevenção
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT01730534 . Published 2018. 0 Comente. 1 2 3 4 5 6 7 · Página anterior.
-
#40Clinical Trials | McGovern Medical School
... Study Status: Closed for new enrollment; Study Website Link: http://clinicaltrials.gov/show/NCT01730534; Principal Investigator: Dr. Francisco Fuentes.
-
#41Comments - DocGuide
... tended to be larger in obese patients with T2DM. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01730534.
-
#42钠-葡萄糖共转运蛋白2抑制剂减少糖尿病肾脏事件
而正在进行的DECLARE-TIMI-58 study（NCT01730534）也包括肾脏结局的分析。研究表明，这种肾脏保护作用是独立于降糖、降压和减重作用的，了解其背后的 ...
-
#43DECLARE TIMI 58 RESEARCH PROTOCOL TITLE
http://clinicaltrials.gov/ct2/show/NCT01730534?term=dapagliflozin&rank=33. STUDY PURPOSE. Patients who have type 2 diabetes are at a higher risk to have ...
-
#44Resources and tools - International Diabetes Federation
2015. https://clinicaltrials.gov/ct2/show/NCT01730534. Last accessed October 2015. 3. ClinicalTrials.gov. Does Saxagliptin reduce the risk ...
-
#45Sodium-glucose cotransporter-2 inhibition for the reduction of ...
Clinicaltrials.gov, NCT01131676, NCT01032629, NCT01730534, NCT01986881. Intervention, Empagliflozin vs. Placebo (2:1), Canagliflozin vs.
-
#46Researchers Study the Potential Impact of Dapagliflozin on ...
Researchers conducted a secondary exploratory analysis of data from the DECLARE-TIMI 58 trial (ClinicalTrials.gov Identifier: NCT01730534) ...
-
#47Improving multi-morbidity with anti-diabetes therapies - RCP ...
NCT01730534. VERTIS. NCT01986881. SGLT2-i empaglifozin canagliflozin dapagliflozin ertugliflozin. Comparator placebo placebo placebo placebo.
-
#48Download (17kB) - The University of Liverpool Repository
Unique identifier: NCT01730534) will provide additional important information in terms of potential cardiovascular benefits of SGLT-2i in patients without ...
-
#49Sodium-glucose co-transporter 2 inhibitors and associated ...
Available from: https://clinicaltrials.gov/ct2/show/NCT01730534 14. U.S Food and Drug Administration. SGLT2 inhibitors: drug safety ...
-
#50探討SGLT2 抑制劑對於第2 型糖尿病合併慢性腎疾病的影響與 ...
cardiovascular events，NCT01730534)，Wiviott. 等學者發表於2018 年NEJM 期刊，該試驗在. 33 個國家882 個地點完成，病患隨機雙盲分配.
-
#51Dapagliflozin and cardiovascular outcomes - Taylor & Francis ...
implications of a recent CVOT [NCT01730534; DECLARE-TIMI 58 study], which demonstrated that dapagliflozin was non-inferior to placebo in ...
-
#52Timothy F. O'Neill, MD - Los Alamitos Cardiovascular
NCT01730534 | http://clinicaltrials.gov/ct2/show/NCT01730534. • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled,.
-
#53IHS PROVIDER September 2017 - Indian Health Service
completed in April 2019 (ClinicalTrials.gov Identifier: NCT01730534). Uncertainty remains regarding the current data, long-.
-
#54SupplementarytableandFigures.docx - Research Square
Kato, 2019, Dapagliflozin, NCT01730534 (DECLARE–TIMI 58 trial), 1987, HFrEF + HFpEF, Dapagliflozin 10mg (980 pts) Placobo (1007pts), 151/980, 194/1007 ...
-
#55Dapagliflozin Appears to Be a Safe Option in Patients with ...
The DECLARE–TIMI 58 trial (NCT01730534. opens in new tab) tested the effect of dapagliflozin in people with diabetes who had, ...
-
#56Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 ...
... regardless of the patient's previous history of AF, atherosclerotic cardiovascular disease, or HF. Registration: URL: ; Unique identifier: NCT01730534.
-
#57Cardiovascular outcome trials of glucose-lowering strategies ...
Besides the TOSCA.IT trial, four additional ongoing cardiovascular outcome trials (NCT00790205, NCT01144338, NCT01730534, ISRCTN91899513) of ...
-
#58Revista ALAD Volumen 5 Número 1 - Issuu
En: http://clinicaltrials.gov/show/ NCT01730534. 92. CANVAS trial. En: http://clinicaltrials.gov/show/NCT01032629 93. Tahara A, Kurosaki E, ...
-
#59Muthu Vaduganathan on Twitter: "@hswapnil @NephRodby ...
ClinicalTrials.gov Identifier: NCT01730534. 7:42 PM · Nov 23, 2021·Twitter for iPhone.
-
#60View of Effects of DAPAgliflozin on CARDiac substrate uptake ...
DECLARE-TIMI 58 [NCT01730534]),. with results expected in the second half of 2018 (. 7. ). A number of potential mechanisms have been suggested.
-
#61ConceptQL - OHDSI
NCT01730534. • Assume NLP extracts criteria. • Match criteria against Jigsaw Algorithm. Repository (JAR). • Use Jigsaw Study Builder to design and.
-
#62Sodium-glucose cotransporter-2 inhibitors and cardiovascular ...
Available online: https://clinicaltrials.gov/ct2/show/NCT01730534; Safety and effectiveness of SGLT-2 inhibitors in patients with heart failure and diabetes ...
-
#63Dapagliflozin and cardiovascular outcomes: anything else to ...
... trial design, results and implications of a recent CVOT [NCT01730534; DECLARE-TIMI 58 study], which demonstrated that dapagliflozin was ...
-
#64Dapagliflozin - Addendum zum Auftrag A19-53 - Version 1.0
Schlagwörter: Dapagliflozin, Diabetes Mellitus – Typ 2, Nutzenbewertung, NCT01730534. Keywords: Dapagliflozin, Diabetes Mellitus – Typ 2, ...
-
#65The clinical landscape of managing patients with CKD - PACE ...
Available at https://clinicaltrials.gov/ct2/show/NCT01730534; 3. NCT02065791. Available at https://clinicaltrials.gov/ct2/show/NCT02065791; ...
-
#665/16/2018 1 The Heart of the Matter: Putting Cardiovascular ...
https://www.clinicaltrials.gov/show/NCT01730534. Accessed April 6, 2017; 2. TIMI Study Group. http://www.timi.org/index.php?page=declare- ...
-
#67The impact of dapagliflozin on cardiovascular system in the ...
6–8. https://www.clinicaltrials.gov/ct2/show/NCT01730534 (2017). Important: This website uses cookies. More >>.
-
#68mmc1.docx
2, Kato-2019, Dapagliflozin, NCT01730534 (DECLARE–TIMI 58 trial), 1987, 151/980, 194/1007, 92/980, 130/1007, 79/980, 85/1007, 122/980, 149/1007.
-
#69U.S. FDA approves FARXIGA™ (dapagliflozin) tablets for the ...
http://clinicaltrials.gov/show/NCT01730534. Accessed November 26, 2013. 5. Centers for Disease Control and Prevention. National Diabetes ...
-
#70The Empagliflozin Cardiovascular Outcome Event Trial in ...
Available from:. https://clinicaltrials.gov/ct2/show/NCT01730534. (updated 2016 Jan 8). 19. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, ...
-
#71Following the results of the EMPA-REG OUTCOME trial with ...
NLM identifier: NCT01730534. Accessed November 7, 2016. 15. Janssen Research & Development; The George Institute for Global Health (Australia) ...
-
#72Chronic Kidney Disease Latest Advances - MediFind
DECLARE-TIMI 58 is registered with ClinicalTrials.gov, number NCT01730534. Findings: The trial took place between April 25, 2013, and Sept 18, 2018; ...
-
#73Dapagliflozin Appears to Be a Safe Option in - ProQuest
The DECLARE-TIMI 58 trial (NCT01730534) tested the effect of dapagliflozin in people with diabetes who had, or were at high risk for, cardiovascular disease ...
-
#74Impact of SGLT2i on cardiovascular outcomes and heart ...
Identifier NCT01730534, Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58), 2017.
-
#75FARXIGA Achieved a Positive Result in the Phase III ...
Accessed September 2018. https://clinicaltrials.gov/ct2/show/NCT01730534. US-22108. View source version on businesswire.com: ...
-
#76Case-Based Examination of Treatment Options in Type 2 ...
NCT01730534. https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed June 29, 2016. Rosenstock J, Chuck L, González-Ortiz M, et al.
-
#77Dapagliflozin and cardiovascular outcomes in type 2 diabetes
(Funded by AstraZeneca; DECLARE–TIMI 58 ClinicalTrials.gov number, NCT01730534.) Item Type: Article. Additional Information: The authors' ...
-
#78Impact and Importance of the 2008 Guidance in Diabetes Care
NCT01730534. •. NCT01394952. •. NCT02065791. •. NCT02479399. •. NCT01986881. •. NCT02465515. •. NCT00700856. *figure not a comprehensive list ...
-
#79The Role of a Preventive Cardiologist in Managing the ...
2012 Nov 21. Identifier NCT01730534, Multicenter Trial to Evaluate the Effect of Dapagloflozin on the Incidence of Cardiovascular Events ( ...
-
#80Farxiga achieved a positive result in the ... - PCRonline.com
2018. https://clinicaltrials.gov/ct2/show/NCT01730534. Source: AstraZeneca. PCR online logo. By and For the Interventional Cardiovascular ...
-
#81Frontiers in Clinical Drug Research - Diabetes and Obesity: ...
[http://dx.doi.org/10.1186/s12933-016-0356-y] [PMID: 26895767] NCT01730534. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of ...
-
#82Renal Disease and coronary, peripheral and structural ...
In subanalysis of DECLARE-TIMI 58 (NCT01730534) randomized trial, the use of dapagliflozin was shown to prevent progression to renal failure in diabetic ...
-
#83Braunwald's Heart Disease E-Book: A Textbook of ...
... Started 4/2013 NCT01730534 DECLARE-TIMI 58 CARMELINA Linagliptin versus glimepiride Dulaglutide Dapagliflozin Linagliptin Ertugliflozin Canagliflozin ...
-
#84Frontiers in Clinical Drug Research - Diabetes and Obesity: ...
... CANVAS PROGRAM (NCT01032629), and DECLARE–TIMI 58 (NCT01730534) have clearly shown a significant reduction in HHF in all the three CVOTs.
-
#85Heart Failure - 第 45 頁 - Google 圖書結果
... of which the DECLARE-TIMI 58 trial (dapagliflozin versus placebo; NCT01730534) and the CREDENCE trial (canagliflozin versus placebo; NCT02065791), ...
-
#86Chronic Kidney Disease, Dialysis, and Transplantation ...
Available at https://clinicaltrials.gov/ct2/show/NCT01730534. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in ...
-
#87Suite 305 233 E. Lancaster Ave. Ardmore, PA 19003 , Affiliate ...
... enrolled in randomized, double-blind, multinational, placebo-controlled phase 3 trial (DECLARE-TIMI 58, ClinicalTrials.gov Identifier: NCT01730534).
-
#88大山 宗馬 (Kazuma Oyama) - Obesity and effects of dapagliflozin on ...
<title>Clinical trial registration</title> URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01730534. </sec>. リンク情報.